Johnson & Johnson | Vision
As J&J MedTech, a leader in eye health, we are paving the way for a new future of vision care at every stage of life.
As J&J MedTech, a leader in eye health, we are paving the way for a new future of vision care at every stage of life.
LIPIFLOW is a pioneering medical device company in the Biotechnology and Health Care industries. Founded in 2005 and headquartered in the United States, the company focuses on improving the evaluation and treatment of meibomian gland dysfunction (MGD), which is the root cause of dry eye and affects approximately 86% of the 300 million dry eye sufferers worldwide. Their innovative technologies, including LipiView II and new LipiScan with Dynamic Meibomian Imaging™ (DMI), allow for distinctive imaging of meibomian gland structure. Additionally, the Korb Meibomian Gland Evaluator™ assists physicians in assessing gland function, while LipiFlow utilizes Vectored Thermal Pulse™ (VTP) technology to precisely direct treatment, receiving clearance by the US Food and Drug Administration.
The company secured a noteworthy $19.23M Series D investment on 14 April 2016, with funding from prominent investors such as EW Healthcare Partners, General Catalyst, Investor Growth Capital, De Novo Ventures, and HealthCare Royalty Partners. Sponsored and unsponsored multicenter, randomized, controlled clinical studies of LipiFlow consistently showcased its safety and sustained effectiveness, highlighting its potential in addressing a prevalent healthcare issue.
LIPIFLOW's commitment to advancing the evaluation of MGD and improving the quality of life for patients with this condition underscores its potential for growth and impact within the healthcare industry.
There is no investment information
No recent news or press coverage available for Johnson & Johnson | Vision.
We care about your data, and we'd love to use cookies make your experience better.
